ArticleCureus2026
Clinical, Epidemiological, and Mycological Characteristics of Dermatophyte Infections: A Cross-Sectional Study From a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDermatophyte infection is a prevalent infection of the skin, hair, and nails caused by a fungus of multiple genera. The distribution and frequency of dermatophytosis vary with the geographical region and various epidemiological factors.
aimThis study aimed to describe the clinical-epidemiological and mycological profile of dermatophytosis and observed the response of systemic antifungals in cases of tinea corporis and tinea cruris. METHODOLOGY: A descriptive cross-sectional study was carried out among 338 patients of clinically diagnosed cases of dermatophyte infection presented to the dermatology outpatient department in a tertiary care hospital between January 2014 and March 2015, considering inclusion and exclusion criteria. Sample collection for fungal elements was done from skin scraping, nail clippings, and hair plucks.
resultsOut of 338 patients included in the study, 212 (62.7%) were males, and 126 (37.3%) were females. The mean age of patients was 30.7 ± 14.5 years. The maximum number of patients (51.8%) was in the age group of 21-40 years. Maximum patients were laborers by occupation (28.7%) and belonged to the lower middle class (53.9%). The majority of 103 (30.47%) patients reported in July. The most common symptom was itching, noted in all 338 (100%) patients, followed by scaling in 294 (87%) of patients. Annular erythematous plaque with scaling (261 (76%)) was the most common clinical finding. Two hundred eighty-two (83.43%) patients reported sharing fomites, while 239 (70.71%) patients had contact with infected family members. Forty-two percent of patients were wearing tight-fitting clothes daily. Two hundred sixty-eight (79.29%) patients had a history of use of different topical medications in the past, and 64 (18.8%) patients reported a history of systemic antifungals taken in the past six months. Comorbid conditions were seen in 80 (23.67%) patients. One hundred twelve (33.13%) were overweight, 54 (15.9%) were obese, and 39 (11.53%) patients were underweight. Tinea corporis was the most common clinical pattern seen in 100 patients (29.5%), followed by tinea cruris in 75 patients (22.3%). Direct microscopy with KOH was positive in 273 (80.76%) patients, whereas culture was positive in 160 (46. 74%) patients.
conclusionYoung male patients of the lower-middle-class family having a positive family history of dermatophytosis were more prone to dermatophytic infections. Overall, these findings highlight the multifactorial epidemiology of dermatophytosis, reaffirm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.